PeptiDream Inc
TSE:4587

Watchlist Manager
PeptiDream Inc Logo
PeptiDream Inc
TSE:4587
Watchlist
Price: 2 551 JPY -0.74% Market Closed
Market Cap: 331.7B JPY
Have any thoughts about
PeptiDream Inc?
Write Note

PeptiDream Inc
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

PeptiDream Inc
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
PeptiDream Inc
TSE:4587
Total Equity
ÂĄ58.5B
CAGR 3-Years
33%
CAGR 5-Years
28%
CAGR 10-Years
26%
GNI Group Ltd
TSE:2160
Total Equity
ÂĄ33.1B
CAGR 3-Years
21%
CAGR 5-Years
25%
CAGR 10-Years
22%
Takara Bio Inc
TSE:4974
Total Equity
ÂĄ115.8B
CAGR 3-Years
11%
CAGR 5-Years
12%
CAGR 10-Years
7%
Pharma Foods International Co Ltd
TSE:2929
Total Equity
ÂĄ11.5B
CAGR 3-Years
9%
CAGR 5-Years
27%
CAGR 10-Years
13%
S
StemRIM Inc
TSE:4599
Total Equity
ÂĄ8.9B
CAGR 3-Years
-6%
CAGR 5-Years
28%
CAGR 10-Years
N/A
C
Cuorips Inc
TSE:4894
Total Equity
ÂĄ6B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

PeptiDream Inc
Glance View

Market Cap
330.6B JPY
Industry
Biotechnology

PeptiDream Inc., a biopharmaceutical powerhouse based in Japan, has carved out a formidable niche by leveraging its proprietary Peptide Discovery Platform System (PDPS) to revolutionize drug development. Founded in 2006 by a team of visionary scientists, the company has positioned itself at the cutting edge of peptide therapeutics. By using the PDPS, PeptiDream identifies and optimizes macrocyclic peptide candidates that have the potential to address a myriad of complex diseases with unmet medical needs. This platform enables the company to create highly specific peptide-based drugs that can modulate challenging targets previously deemed “undruggable” by conventional methods. For PeptiDream, innovation isn’t just a mission statement but an operational ethos that drives its strategic collaborations and partnerships across the pharmaceutical landscape. Revenue generation at PeptiDream is predominantly through multi-faceted strategic collaborations with leading global pharmaceutical companies. By partnering with industry titans, PeptiDream licenses access to its cutting-edge PDPS technology and collaborates on drug discovery and development projects. This collaborative approach allows the company to secure upfront payments, research funding, milestone payments, and potential royalties on the eventual sales of successfully commercialized drugs. By securing a steady stream of income through these partnerships, PeptiDream not only sustains its robust research and development initiatives but also fuels an innovation pipeline that positions it as a leader in the burgeoning field of peptide-based therapeutics.

Intrinsic Value
2 516.1 JPY
Overvaluation 1%
Intrinsic Value
Price

See Also

What is PeptiDream Inc's Total Equity?
Total Equity
58.5B JPY

Based on the financial report for Sep 30, 2024, PeptiDream Inc's Total Equity amounts to 58.5B JPY.

What is PeptiDream Inc's Total Equity growth rate?
Total Equity CAGR 10Y
26%

Over the last year, the Total Equity growth was 56%. The average annual Total Equity growth rates for PeptiDream Inc have been 33% over the past three years , 28% over the past five years , and 26% over the past ten years .

Back to Top